BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 20, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 30, 2022

View Archived Issues
Stock-crashes.png

Neogenomics CEO departs, revenue guidance pulled

Neogenomics Inc. stunned investors, reporting that Mark Mallon would step down as CEO and board member, effectively immediately. Tuesday’s unexpected announcement – coupled with news that first-quarter revenue could miss prior guidance – sent Neogenomics stock (Nasdaq: NEO) down 29.8% to close at $12.49, and triggered a 52-week low of $11.00 earlier in the day. Read More
03-30-VivoSense_Three.png

Vivosense collects $25M to develop digital biomarkers

Vivosense Inc. aims to improve clinical trial recruitment and outcomes by developing new digital biomarkers and clinical outcome assessments (COAs) that use data from wearable devices, a goal made a touch easier by its successful completion of a $25 million series A financing round. The company’s platform is designed to detect and rigorously interpret subtle shifts in physiology using body-worn sensors. Read More
washington-congress-capital.png

FDA’s Shuren says secrecy, speed trump transparency for user fee meeting minutes

Negotiations between the U.S. FDA and industry over device user fees were a protracted struggle, but the agency was demonstrably loathe to post the minutes from meetings between the agency and industry representatives. Jeff Shuren, director of the FDA’s device center, said in a congressional hearing that those minutes were not posted because of a need to wrap up the negotiations rather than allow outsiders – including members of Congress – to see how difficult the negotiations had become. Read More
03-30-Qure-qremote-mock-up.png

Qure eyes US and Europe expansion for AI imaging diagnostics portfolio

Health tech firm Qure.ai Technologies Private Ltd. has secured a $40 million investment from investors including Novo Holdings and Healthquad to expand its portfolio of automated artificial intelligence (AI)-based imaging diagnostics. The company’s suite of technologies incorporates deep learning and AI to interpret radiology images such as X-rays, CTs, and ultrasounds in less than a minute. Read More
Illustration of pill being analyzed

Elix and Shionogi partner to validate retrosynthetic analysis model to discover drugs

Elix Inc. has teamed up with Shionogi & Co. Ltd. to validate a retrosynthetic analysis model for drug discovery that will employ chemical reaction data from Shionogi to explore various routes to synthesizing new molecules. Read More

NICE sees need for more evidence for Prontosan wound care product

The U.K. National Institute for Health and Care Excellence said its review of the Prontosan line of wound care products by B. Braun Medical AG of Melsungen, Germany, may be a cost saver for the National Health System compared to saline flush for chronic wounds. However, the agency also noted that most of the evidence of the effectiveness is of “not good quality,” suggesting that the company conduct more clinical trials to cover the evidence gap. Read More

Appointments and advancements for March 30, 2022

New hires and promotions in the med-tech industry, including: Advanced Ostomy Tools, Contraline, Delfi Diagnostics, Innovheart, M2gen, Tissuevision, Voxneuro. Read More

Financings for March 30, 2022

Med-tech firms raising money in public or private financings, including: Altoida, Baymatob, Billiontoone, Inner Cosmos, Irhythm. Read More

In the clinic for March 30, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Masimo, O'Brien, Synchron, University of Portsmouth. Read More

Other news to note for March 30, 2022

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biosig, Caire, Caredx, Curi Bio, Elekta, Hologenix, Keen Eye, Medanex, Medline, Namsa, Quanterix, Stembiosys, Ultivue. Read More

Regulatory actions for March 30, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aidoc, Cartiheal, Life Spine, Nanovibronix, Optellum, Shockwave Medical. Read More

Popular Stories

  • Today's news in brief

    BioWorld

    BioWorld briefs for March 19, 2026.

  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing